News from the FDA/CDC

FDA approves long-acting ESA for dialysis-related anemia in children, adolescents


 

The Food and Drug Administration has approved methoxy polyethylene glycol-epoetin beta (Mircera) for the treatment of dialysis-related anemia in pediatric patients aged 5-17 years with chronic kidney disease whose hemoglobin had been stabilized with an erythropoiesis-stimulating agent (ESA).

FDA icon
The approval for this long-acting ESA was based on an open-label dose-finding trial of 64 patients aged 5-17 years. All patients had chronic kidney disease and were on hemodialysis, and had been previously treated with another ESA and achieved stable hemoglobin levels. Patients received Mircera intravenously every 4 weeks based on the total weekly dose of the previously used ESA (either epoetin alfa/beta or darbepoetin alfa), with dosage adjustments after the first dose as needed to maintain target hemoglobin levels.

Efficacy was based partly on how well target hemoglobin levels were maintained in this trial, but also on extrapolation from results of trials in adults. The safety profile in these pediatric patients was consistent with those previously observed in adults. Mircera is manufactured by Vifor Pharma.

More information on the approval of Mircera in this population can be found in the FDA release. The prescribing information for Mircera, initially approved in 2007, has also been updated.

Recommended Reading

FDA approves first new drug for sickle cell in nearly 20 years
MDedge Pediatrics
Allele-matching in cord blood transplant yields better survival
MDedge Pediatrics
L-glutamine to prevent sickle cell complications featured in FDA podcast
MDedge Pediatrics
Guidelines cut acute chest syndrome hospital returns in pediatric sickle cell
MDedge Pediatrics
Emerging sickle cell agents target new pathways
MDedge Pediatrics
Clinic eases pediatric-adult transition in sickle cell disease
MDedge Pediatrics
FDA approves hydroxyurea for pediatric patients with sickle cell anemia
MDedge Pediatrics
FDA grants breakthrough therapy designation for severe aplastic anemia drug
MDedge Pediatrics
Children with sickle cell anemia fall short on antibiotic adherence
MDedge Pediatrics
Too few Michigan children with SCD receive pneumococcal, meningococcal vaccines
MDedge Pediatrics